Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Key Takeaways for Investors

• Accelerated enrollment in Phase 3 CoMpass trial for early choroidal melanoma; completion expected mid-2026, topline data anticipated second half of 2027.
• Phase 1b/2 NMIBC (non-muscle invasive bladder cancer) trial progressing; initial 3-month data expected mid-2026.
• New drug formulation achieves 12-month stability, opening opportunities for non-ocular solid tumors, starting with bladder cancer. Patent application filed, potential coverage to 2046.
• Strong cash position: \$144.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025; runway into Q1 2027.
• Net loss increased to \$106.2 million for FY2025, up from \$86.9 million in FY2024, driven by expanded clinical activity and personnel costs.
• Multiple clinical programs advancing in ocular and non-ocular oncology, including new trials for metastases to the choroid and cancers of the ocular surface.

Clinical Pipeline Highlights

Early Choroidal Melanoma

Aura Biosciences’ global, randomized Phase 3 CoMpass trial is the first registration-enabling study for early choroidal melanoma. The trial is evaluating their lead candidate, bel-sar (AU-011), versus sham control, using an enrichment strategy for patients with documented tumor growth. Accelerated enrollment is expected to complete by mid-2026, with topline data for the 15-month primary endpoint in 2H 2027.

Bel-sar has received Orphan Drug Designation from both the FDA and EMA, and Fast Track designation from the FDA. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Aura’s patient identification tool is expanding, reflecting unmet need and potential for bel-sar as the first vision-preserving frontline therapy in early choroidal melanoma.

Bladder Cancer (NMIBC)

The ongoing Phase 1b/2 NMIBC trial is evaluating bel-sar in intermediate- and high-risk patients, with initial 3-month clinical data expected mid-2026. Two approaches are being tested: immune ablative (bel-sar administered without transurethral resection of bladder tumor, TURBT), and neoadjuvant (bel-sar before TURBT). Response and recurrence are monitored at 3, 6, 9, and 12 months, along with safety.

Aura’s new formulation for non-ocular solid tumors, beginning with bladder cancer, has achieved 12-month stability. With convenient refrigeration and no need for cold chain, it supports in-office administration by urologists. A patent application has been filed for this formulation, potentially extending patent coverage to 2046.

Metastases to the Choroid

Aura is enrolling patients in a Phase 2 trial for bel-sar in choroidal metastases, designed for patients with metastases from various primary solid tumors. Early proof-of-concept data, based on a four-week efficacy endpoint, is expected in 2026. This indication has high unmet medical need (~20,000 annual cases in US and Europe) and no approved therapies. Bel-sar has FDA Fast Track designation in this indication.

Cancers of the Ocular Surface

Aura is initiating a Phase 1 proof-of-concept trial in Australia to evaluate safety, feasibility, and tumor response for cancers of the ocular surface. Early data is expected in 2026. This indication affects ~35,000 patients annually in US/Europe, with particularly high incidence in Australia, and currently lacks approved therapies.

Financial Results

• Cash, cash equivalents, and marketable securities: \$144.2 million as of December 31, 2025. Management projects sufficient funds to operate into Q1 2027.
• Research & Development expenses: \$21.9 million in Q4 2025 and \$90.3 million for FY2025 (up from \$73.3 million in FY2024), driven by expansion of clinical programs and increased personnel.
• General & Administrative expenses: \$5.3 million in Q4 2025, \$22.5 million for FY2025 (slightly down from \$22.8 million in FY2024), with reduced professional fees.
• Net loss: \$25.6 million in Q4 2025, \$106.2 million for FY2025 (compared to \$25.8 million and \$86.9 million in Q4/FY2024).
• Shares outstanding: Weighted average shares outstanding increased to 60.3 million in 2025, up from 49.7 million in 2024.
• Comprehensive loss: \$106.6 million for FY2025, vs. \$87.2 million in FY2024.

Balance Sheet

• Total assets: \$169.4 million as of December 31, 2025 (down from \$182.5 million in 2024).
• Total liabilities: \$32.5 million as of December 31, 2025 (up from \$30.5 million in 2024).
• Total stockholders’ equity: \$136.9 million as of December 31, 2025 (down from \$152.0 million in 2024).
• Increase in additional paid-in capital: \$617.4 million in 2025, up from \$525.9 million in 2024.
• Accumulated deficit: (\$480.4 million) in 2025, up from (\$374.2 million) in 2024.

Potential Price Sensitive Elements for Shareholders

• Accelerated Phase 3 enrollment and clear topline data timeline: Mid-2026 enrollment completion for CoMpass trial, topline data in 2H 2027.
• New product formulation with patent application: Potential to differentiate product in non-ocular solid tumors, supporting broader market opportunity and longer intellectual property protection (to 2046).
• Multiple near-term clinical readouts: Initial NMIBC trial data (mid-2026), early data from metastases to the choroid and ocular surface cancer trials in 2026.
• Strong cash runway: Sufficient capital to fund operations into Q1 2027, reducing near-term capital risk.
• Expansion into non-ocular oncology: May significantly broaden addressable market.
• Increasing net loss and R&D spend: Reflects ramped up clinical activity, but may also affect investor sentiment on profitability timeline.
• Intellectual property protection: Patent application for new formulation, if granted, strengthens competitive position.

Company Overview

Aura Biosciences is a clinical-stage biotech specializing in precision therapies for solid tumors with a focus on organ preservation. Its lead candidate, bel-sar (AU-011), is advancing through late-stage development for early choroidal melanoma and early-stage development in other ocular oncology and bladder cancer indications. The company is headquartered in Boston, MA, and aims to become a global leader in oncology innovation.

Forward-Looking Statements Disclaimer

This article contains forward-looking statements regarding Aura Biosciences’ pipeline, clinical trial progress, financial projections, and intellectual property. These statements are subject to risks and uncertainties, including clinical trial outcomes, regulatory review, market acceptance, cash runway, and competitive factors. Actual results may differ materially from those expressed or implied. Investors should review company filings with the SEC for detailed risk disclosures and should not place undue reliance on these statements. The company undertakes no obligation to update forward-looking statements except as required by law.

View Aura Biosciences, Inc. Historical chart here